Last Price | 0.29 | Max Price | 0.29 |
Min Price | 0.29 | 1 Year return | -45.28 |
Avg. Target | 0.00 | Expected Return | -100.00 % |
Sector | Health Care | Subsector | Biotechnology |
Sell | 0 | Rating | |
Hold | 0 | Concensus | |
Buy | 0 | ||
Annual report 2015 |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 37 | 141,925 | 0.03 % |
2020 | 43 | 170,231 | 0.03 % |
2021 | 48 | 252,886 | 0.02 % |
2022 | 57 | 238,496 | 0.02 % |
2023 | 0 | 0 | 0.00 % |
Analysts expect over 2023 growing sales Biocartis
Analysts expect over 2023 revenue increase Biocartis
Analysts expect revenue increase Biocartis
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
The period between December 2015 and December 2016 was a bad period for the investors. The stock lost almost 22 percent. Over the past 5 years Biocartis' stock lost at around 0 percent in value.
The past 10 years the (international) industry gained at around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.
The French company didn't pay out any dividends (in the past 5 years).
At the end of 2015 the biotech company's balance sheet equaled 0 million euros. The total debt of the biotech company was at the end of 2015 0 million euros, which equals around percent of the total balance sheet.
All Biocartis's financial reports are located here. More information about Biocartis can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
13
|
12
|
21
|
28
|
37
|
43
|
Costs |
53
|
62
|
63
|
76
|
102
|
106
|
Profit |
-40
|
-50
|
-42
|
-48
|
-64
|
-63
|
Margin of profit |
-298.57
|
-411.40
|
-200.19
|
-173.14
|
-171.13
|
-145.91
|
ROI |
-34.63
|
-51.38
|
-31.73
|
-55.12
|
-75.84
|
-170.91
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
115
|
97
|
132
|
87
|
84
|
37
|
Debt |
33
|
44
|
49
|
52
|
184
|
174
|
Total assets |
148
|
141
|
181
|
139
|
268
|
211
|
Solvency |
77.45
|
68.57
|
72.98
|
62.67
|
31.48
|
17.49
|
Cash |
104
|
82
|
112
|
62
|
178
|
122
|
Cashflow |
-27
|
-53
|
-41
|
-42
|
-54
|
-39
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-0.82
|
-1.20
|
-0.85
|
-0.81
|
-0.30
|
-0.23
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
11.52
|
9.56
|
10.42
|
8.67
|
4.99
|
Eps |
-1.06
|
-0.81
|
-0.82
|
-1.00
|
-0.97
|
Price/earnings-ratio |
-10.87
|
-11.80
|
-12.71
|
-8.67
|
-0.30
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
1.89
|
2.26
|
1.48
|
1.31
|
0.56
|
Market to book |
0.16
|
0.24
|
0.14
|
0.15
|
1.92
|
Cashflow per stock |
-1.04
|
-0.71
|
-0.71
|
-0.84
|
-0.60
|
Stocks |
51
|
59
|
59
|
65
|
66
|
Market Cap |
589.65
|
560.06
|
613.54
|
560.40
|
19.13
|
Date
|
Price
|
---|---|
13 Nov 2024
|
0.29
|
08 Nov 2024
|
0.29
|
05 Nov 2024
|
0.29
|
31 Oct 2024
|
0.29
|
29 Oct 2024
|
0.29
|
23 Oct 2024
|
0.29
|
19 Oct 2024
|
0.29
|
16 Oct 2024
|
0.29
|
14 Oct 2024
|
0.29
|
05 Oct 2024
|
0.29
|
02 Oct 2024
|
0.29
|
27 Sep 2024
|
0.29
|
20 Sep 2024
|
0.29
|
17 Sep 2024
|
0.29
|
13 Sep 2024
|
0.29
|
28 Aug 2024
|
0.29
|
26 Aug 2024
|
0.29
|
23 Aug 2024
|
0.29
|
11 Aug 2024
|
0.29
|
07 Aug 2024
|
0.29
|
05 Aug 2024
|
0.29
|
01 Aug 2024
|
0.29
|
30 Jul 2024
|
0.29
|
26 Jul 2024
|
0.29
|
23 Jul 2024
|
0.29
|
16 Jul 2024
|
0.29
|
10 Jul 2024
|
0.29
|
09 Jul 2024
|
0.29
|
04 Jul 2024
|
0.29
|
02 Jul 2024
|
0.29
|